Neogenomics (NEO) Stock Price
Neogenomics Price
Over the last 19 years Neogenomics grew revenue by 28.2% annually, reaching 727.33 M USD. Earnings per share have grown at 50.4% per year over the last 8 years. For Neogenomics, the net margin of -14.9% is down versus -1.7% a few years ago. The consensus 12-month price target for Neogenomics is 19.00 USD, about 15.2% above where the stock trades today. Of 16 analysts, 11 rate the stock a buy — an overall Buy consensus.
Neogenomics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Neogenomics business model & stock analysis
Frequently asked questions about Neogenomics
Neogenomics Inc. (NYSE: NEO) is a leading provider of cancer-focused genetic testing services. The company's business model revolves around offering comprehensive testing solutions that aid in the diagnosis and treatment of cancer patients. Neogenomics Inc. operates through a network of laboratories and provides advanced molecular and cytogenetic testing, helping healthcare professionals make informed decisions based on genetic information. With a focus on precision medicine, Neogenomics Inc. delivers personalized treatment options, improving patient outcomes and delivering high-quality diagnostic services.
Neogenomics Inc is primarily active in the healthcare and diagnostic laboratory services industries.
The main competitors of Neogenomics Inc in the market are Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, and NeoGenomics Laboratories.
Neogenomics Inc is a leading provider of cancer-focused genetic testing services. Founded in 2001, the company is headquartered in Fort Myers, Florida. With an extensive network of laboratories across the United States, Neogenomics offers cutting-edge diagnostic and pharmaceutical services to aid in the personalized treatment and monitoring of various types of cancers. Over the years, Neogenomics has grown its portfolio of tests and services, catering to the evolving needs of healthcare professionals and patients. Their dedication to innovation and quality has positioned them as a trusted partner in the fight against cancer.
Some significant milestones achieved by Neogenomics Inc include its acquisition of Clarient Inc in 2015, which expanded its personalized medicine capabilities. The company also received full approval from the New York State Department of Health in 2017, allowing it to offer its services in all 50 states. Neogenomics Inc has strengthened its position in the molecular testing market through strategic collaborations with pharmaceutical companies. Furthermore, in 2019, the company completed its acquisition of Genoptix, enhancing its oncology diagnostics capabilities. These milestones demonstrate Neogenomics Inc's commitment to growth and innovation in the field of cancer diagnostics and personalized medicine.
Neogenomics Inc is primarily present in the United States.
Neogenomics Inc prides itself on its commitment to excellence and innovation in the field of precision medicine. With a strong corporate philosophy centered around patient care and advancing the fight against cancer, Neogenomics Inc places great importance on ethical practices and providing accurate diagnostic solutions. The company believes in fostering a collaborative environment to bring cutting-edge technologies and personalized medicine to patients globally. By constantly pushing boundaries and embracing transformative ideas, Neogenomics Inc aims to revolutionize how cancer is detected and treated. Through its dedication to quality, integrity, and patient-centric values, the company sets itself apart as a leader in the field.
Analysts currently set an average price target of 19.00 USD for the Neogenomics stock (median: 19.00 USD), implying +15.2 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Neogenomics stock: 11 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Neogenomics to generate revenue of 805.18 M USD and earnings per share of 0.92 USD.
Converted at the current exchange rate, the Neogenomics share trades at 14.71 EUR (16.50 USD).
The Neogenomics share (NEO) is listed on 5 stock exchanges, including: NASDAQ (NEO), SIX (Zürich) (NG9.SW), Frankfurt (NG9.F), München (NG9.MU), Düsseldorf (NG9.DU).
Neogenomics Inc is a leading company in oncology diagnostics and offers a wide range of solutions and products to its customers. The company has been listed on the stock exchange since 2001 and is the largest provider of cancer diagnostics services in the United States. Translate the text to the best possible English.
The expected revenue of Neogenomics is 805.18 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Neogenomics is 23.72 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Neogenomics is currently 17.90. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neogenomics stock.
The price-to-sales ratio (P/S) of Neogenomics is currently 0.53. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Neogenomics stock.
The Eulerpool Quality Score for Neogenomics is 3/10.
The ISIN of Neogenomics is US64049M2098. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Neogenomics is 120159. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Neogenomics is NEO. The ticker symbol is used to trade Neogenomics shares on the stock exchange.
Neogenomics stock
Neogenomics Peer Group
Neogenomics Ticker
Neogenomics FIGI
All fundamentals and in-depth analysis of Neogenomics
Our stock analysis for Neogenomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neogenomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.